long-term outcomes and toxicities of ibrutinib in cll
Published 10 months ago • 283 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:34
long-term surveillance for cardiac toxicities in patients with hl treated with chemotherapy
-
3:13
cll versus other leukemia types
-
35:50
t-cell memory and exhaustion
-
4:16
how does cll affect sinuses and the skin?
-
1:37
causes & management of ibrutinib discontinuation in cll
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
1:43
long-term outcomes of the ifcg regimen for firstline treatment of patients with ighv-mutated cll
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:19
long-term management of cll for improved outcomes
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
1:49
the future of cll: managing new toxicities and improved categorization
-
2:24
the effectiveness of ibrutinib flexible dosing regimens on ttnt in cll/sll
-
1:58
big data on efficacy and toxicity levels for ibrutinib in cll
-
2:00
associated toxicities of novel therapies for cll
-
1:24
sequencing of btk inhibitors in cll
-
1:19
cll treatment: a look into the future
-
4:17
ibrutinib-rituximab for cll: efficacious, but challenging toxicity profile